首页 > 最新文献

Journal of Pathology and Translational Medicine最新文献

英文 中文
Metallic implant-associated lymphoma: ALK-negative anaplastic large cell lymphoma associated with total knee replacement arthroplasty. 金属假体相关淋巴瘤:与全膝关节置换术相关的alk阴性间变性大细胞淋巴瘤。
IF 2.4 Q2 Medicine Pub Date : 2023-01-01 DOI: 10.4132/jptm.2022.10.30
Jai-Hyang Go

Metallic implant-associated lymphomas are extremely rare. Only seven cases have been reported in association with knee joint arthroplasty, and all tumors were large B-cell lymphomas. This report is the first case of anaplastic large cell lymphoma occurring after total knee replacement arthroplasty. An 80‑year‑old female patient was admitted because of right knee pain for 2 years. She had undergone total knee replacement arthroplasty 10 years prior. Computed tomography showed an irregular osteolytic lesion in the right lateral femoral condyle, adjacent to the metallic prosthesis. Histologic findings reveal sheets of anaplastic tumor cells that were positive for CD2, CD4, CD5, CD43, and CD30 but negative for CD3, CD20, CD15, and anaplastic lymphoma kinase. Epstein-Barr encoding region in situ hybridization was negative. Analysis of T-cell receptor γ gene rearrangement studies using BIOMED-2-based multiplex polymerase chain reaction confirmed monoclonal T cell proliferation. The woman was finally diagnosed with ALK-negative anaplastic large cell lymphoma.

金属植入物相关淋巴瘤极为罕见。仅报道了7例与膝关节置换术相关的病例,所有肿瘤均为大b细胞淋巴瘤。本报告为第一例全膝关节置换术后发生间变性大细胞淋巴瘤。一例80岁女性患者因右膝疼痛2年入院。她在10年前接受了全膝关节置换术。计算机断层扫描显示在金属假体附近的右外侧股骨髁有不规则的溶骨性病变。组织学结果显示间变性肿瘤细胞片CD2、CD4、CD5、CD43和CD30阳性,但CD3、CD20、CD15和间变性淋巴瘤激酶阴性。Epstein-Barr编码区原位杂交阴性。利用基于biomed -2的多重聚合酶链反应分析T细胞受体γ基因重排研究,证实单克隆T细胞增殖。这名妇女最终被诊断为alk阴性间变性大细胞淋巴瘤。
{"title":"Metallic implant-associated lymphoma: ALK-negative anaplastic large cell lymphoma associated with total knee replacement arthroplasty.","authors":"Jai-Hyang Go","doi":"10.4132/jptm.2022.10.30","DOIUrl":"https://doi.org/10.4132/jptm.2022.10.30","url":null,"abstract":"<p><p>Metallic implant-associated lymphomas are extremely rare. Only seven cases have been reported in association with knee joint arthroplasty, and all tumors were large B-cell lymphomas. This report is the first case of anaplastic large cell lymphoma occurring after total knee replacement arthroplasty. An 80‑year‑old female patient was admitted because of right knee pain for 2 years. She had undergone total knee replacement arthroplasty 10 years prior. Computed tomography showed an irregular osteolytic lesion in the right lateral femoral condyle, adjacent to the metallic prosthesis. Histologic findings reveal sheets of anaplastic tumor cells that were positive for CD2, CD4, CD5, CD43, and CD30 but negative for CD3, CD20, CD15, and anaplastic lymphoma kinase. Epstein-Barr encoding region in situ hybridization was negative. Analysis of T-cell receptor γ gene rearrangement studies using BIOMED-2-based multiplex polymerase chain reaction confirmed monoclonal T cell proliferation. The woman was finally diagnosed with ALK-negative anaplastic large cell lymphoma.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/f9/jptm-2022-10-30.PMC9846009.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10596567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
What's new in neuromuscular pathology 2022: myopathy updates and gene therapies. 2022年神经肌肉病理学最新进展:肌病更新和基因治疗。
IF 2.4 Q2 Medicine Pub Date : 2023-01-01 DOI: 10.4132/jptm.2022.10.14
Chunyu Cai

This compilation of new changes in the diagnosis and treatment of muscle and nerve disease is extracted from the latest publications from the European Neuromuscular Centre International workshops, FDA.gov and clinicaltrials.gov.

这份关于肌肉和神经疾病诊断和治疗新变化的汇编摘自欧洲神经肌肉中心国际研讨会、FDA.gov和clinicaltrials.gov的最新出版物。
{"title":"What's new in neuromuscular pathology 2022: myopathy updates and gene therapies.","authors":"Chunyu Cai","doi":"10.4132/jptm.2022.10.14","DOIUrl":"https://doi.org/10.4132/jptm.2022.10.14","url":null,"abstract":"<p><p>This compilation of new changes in the diagnosis and treatment of muscle and nerve disease is extracted from the latest publications from the European Neuromuscular Centre International workshops, FDA.gov and clinicaltrials.gov.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/c6/jptm-2022-10-14.PMC9846006.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9156382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infections and immunity: associations with obesity and related metabolic disorders. 感染和免疫:与肥胖和相关代谢紊乱的关系。
IF 2.4 Q2 Medicine Pub Date : 2023-01-01 DOI: 10.4132/jptm.2022.11.14
Amitabha Ray, Melissa J L Bonorden, Rajashree Pandit, Katai J Nkhata, Anupam Bishayee

About one-fourth of the global population is either overweight or obese, both of which increase the risk of insulin resistance, cardiovascular diseases, and infections. In obesity, both immune cells and adipocytes produce an excess of pro-inflammatory cytokines that may play a significant role in disease progression. In the recent coronavirus disease 2019 (COVID-19) pandemic, important pathological characteristics such as involvement of the renin-angiotensin-aldosterone system, endothelial injury, and pro-inflammatory cytokine release have been shown to be connected with obesity and associated sequelae such as insulin resistance/type 2 diabetes and hypertension. This pathological connection may explain the severity of COVID-19 in patients with metabolic disorders. Many studies have also reported an association between type 2 diabetes and persistent viral infections. Similarly, diabetes favors the growth of various microorganisms including protozoal pathogens as well as opportunistic bacteria and fungi. Furthermore, diabetes is a risk factor for a number of prion-like diseases. There is also an interesting relationship between helminths and type 2 diabetes; helminthiasis may reduce the pro-inflammatory state, but is also associated with type 2 diabetes or even neoplastic processes. Several studies have also documented altered circulating levels of neutrophils, lymphocytes, and monocytes in obesity, which likely modifies vaccine effectiveness. Timely monitoring of inflammatory markers (e.g., C-reactive protein) and energy homeostasis markers (e.g., leptin) could be helpful in preventing many obesity-related diseases.

全球约有四分之一的人口超重或肥胖,这两种情况都增加了胰岛素抵抗、心血管疾病和感染的风险。在肥胖中,免疫细胞和脂肪细胞都会产生过量的促炎细胞因子,这可能在疾病进展中起重要作用。在最近的2019冠状病毒病(COVID-19)大流行中,重要的病理特征,如肾素-血管紧张素-醛固酮系统的参与、内皮损伤和促炎细胞因子释放,已被证明与肥胖及其相关的后遗症(如胰岛素抵抗/ 2型糖尿病和高血压)有关。这种病理联系可以解释COVID-19在代谢紊乱患者中的严重程度。许多研究也报道了2型糖尿病和持续性病毒感染之间的联系。同样,糖尿病有利于各种微生物的生长,包括原生动物病原体以及机会性细菌和真菌。此外,糖尿病是许多朊病毒样疾病的危险因素。蠕虫和2型糖尿病之间还有一个有趣的关系;蠕虫病可能会降低促炎状态,但也与2型糖尿病甚至肿瘤进程有关。几项研究也记录了肥胖患者的中性粒细胞、淋巴细胞和单核细胞循环水平的改变,这可能会改变疫苗的有效性。及时监测炎症标志物(如c反应蛋白)和能量稳态标志物(如瘦素)可能有助于预防许多与肥胖相关的疾病。
{"title":"Infections and immunity: associations with obesity and related metabolic disorders.","authors":"Amitabha Ray,&nbsp;Melissa J L Bonorden,&nbsp;Rajashree Pandit,&nbsp;Katai J Nkhata,&nbsp;Anupam Bishayee","doi":"10.4132/jptm.2022.11.14","DOIUrl":"https://doi.org/10.4132/jptm.2022.11.14","url":null,"abstract":"<p><p>About one-fourth of the global population is either overweight or obese, both of which increase the risk of insulin resistance, cardiovascular diseases, and infections. In obesity, both immune cells and adipocytes produce an excess of pro-inflammatory cytokines that may play a significant role in disease progression. In the recent coronavirus disease 2019 (COVID-19) pandemic, important pathological characteristics such as involvement of the renin-angiotensin-aldosterone system, endothelial injury, and pro-inflammatory cytokine release have been shown to be connected with obesity and associated sequelae such as insulin resistance/type 2 diabetes and hypertension. This pathological connection may explain the severity of COVID-19 in patients with metabolic disorders. Many studies have also reported an association between type 2 diabetes and persistent viral infections. Similarly, diabetes favors the growth of various microorganisms including protozoal pathogens as well as opportunistic bacteria and fungi. Furthermore, diabetes is a risk factor for a number of prion-like diseases. There is also an interesting relationship between helminths and type 2 diabetes; helminthiasis may reduce the pro-inflammatory state, but is also associated with type 2 diabetes or even neoplastic processes. Several studies have also documented altered circulating levels of neutrophils, lymphocytes, and monocytes in obesity, which likely modifies vaccine effectiveness. Timely monitoring of inflammatory markers (e.g., C-reactive protein) and energy homeostasis markers (e.g., leptin) could be helpful in preventing many obesity-related diseases.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/7c/jptm-2022-11-14.PMC9846011.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10596596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Single-cell and spatial sequencing application in pathology. 单细胞和空间测序在病理学中的应用。
IF 1.7 Q3 PATHOLOGY Pub Date : 2023-01-01 Epub Date: 2023-01-10 DOI: 10.4132/jptm.2022.12.12
Yoon-Seob Kim, Jinyong Choi, Sug Hyung Lee

Traditionally, diagnostic pathology uses histology representing structural alterations in a disease's cells and tissues. In many cases, however, it is supplemented by other morphology-based methods such as immunohistochemistry and fluorescent in situ hybridization. Single-cell RNA sequencing (scRNA-seq) is one of the strategies that may help tackle the heterogeneous cells in a disease, but it does not usually provide histologic information. Spatial sequencing is designed to assign cell types, subtypes, or states according to the mRNA expression on a histological section by RNA sequencing. It can provide mRNA expressions not only of diseased cells, such as cancer cells but also of stromal cells, such as immune cells, fibroblasts, and vascular cells. In this review, we studied current methods of spatial transcriptome sequencing based on their technical backgrounds, tissue preparation, and analytic procedures. With the pathology examples, useful recommendations for pathologists who are just getting started to use spatial sequencing analysis in research are provided here. In addition, leveraging spatial sequencing by integration with scRNA-seq is reviewed. With the advantages of simultaneous histologic and single-cell information, spatial sequencing may give a molecular basis for pathological diagnosis, improve our understanding of diseases, and have potential clinical applications in prognostics and diagnostic pathology.

传统上,病理诊断使用组织学方法来描述疾病细胞和组织的结构变化。但在许多情况下,组织学还需要辅以其他基于形态学的方法,如免疫组化和荧光原位杂交。单细胞 RNA 测序(scRNA-seq)是有助于解决疾病中异质性细胞问题的策略之一,但它通常不能提供组织学信息。空间测序的目的是通过 RNA 测序,根据组织切片上的 mRNA 表达来确定细胞类型、亚型或状态。它不仅能提供病变细胞(如癌细胞)的 mRNA 表达,还能提供基质细胞(如免疫细胞、成纤维细胞和血管细胞)的 mRNA 表达。在这篇综述中,我们根据技术背景、组织制备和分析程序研究了目前的空间转录组测序方法。通过病理学实例,我们为刚刚开始在研究中使用空间测序分析的病理学家提供了有用的建议。此外,还对空间测序与 scRNA-seq 的整合进行了综述。空间测序具有同时获得组织学和单细胞信息的优势,可为病理诊断提供分子基础,提高我们对疾病的认识,并在预后和病理诊断方面具有潜在的临床应用价值。
{"title":"Single-cell and spatial sequencing application in pathology.","authors":"Yoon-Seob Kim, Jinyong Choi, Sug Hyung Lee","doi":"10.4132/jptm.2022.12.12","DOIUrl":"10.4132/jptm.2022.12.12","url":null,"abstract":"<p><p>Traditionally, diagnostic pathology uses histology representing structural alterations in a disease's cells and tissues. In many cases, however, it is supplemented by other morphology-based methods such as immunohistochemistry and fluorescent in situ hybridization. Single-cell RNA sequencing (scRNA-seq) is one of the strategies that may help tackle the heterogeneous cells in a disease, but it does not usually provide histologic information. Spatial sequencing is designed to assign cell types, subtypes, or states according to the mRNA expression on a histological section by RNA sequencing. It can provide mRNA expressions not only of diseased cells, such as cancer cells but also of stromal cells, such as immune cells, fibroblasts, and vascular cells. In this review, we studied current methods of spatial transcriptome sequencing based on their technical backgrounds, tissue preparation, and analytic procedures. With the pathology examples, useful recommendations for pathologists who are just getting started to use spatial sequencing analysis in research are provided here. In addition, leveraging spatial sequencing by integration with scRNA-seq is reviewed. With the advantages of simultaneous histologic and single-cell information, spatial sequencing may give a molecular basis for pathological diagnosis, improve our understanding of diseases, and have potential clinical applications in prognostics and diagnostic pathology.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/ca/jptm-2022-12-12.PMC9846004.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10588845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarker testing of cytology specimens in personalized medicine for lung cancer patients. 肺癌个体化治疗中细胞学标本的生物标志物检测。
IF 2.4 Q2 Medicine Pub Date : 2022-11-01 Epub Date: 2022-11-09 DOI: 10.4132/jptm.2022.10.17
Hyojin Kim, Jin-Haeng Chung

Every patient with advanced non-small cell lung cancer (NSCLC) should be tested for targetable driver mutations and gene arrangements that may open avenues for targeted therapy. As most patients with NSCLC in the advanced stage of the disease are not candidates for surgery, these tests have to be performed on small biopsies or cytology samples. A growing number of other genetic changes with targetable mutations may be treatable in the near future. To identify patients who might benefit from novel targeted therapy, relevant markers should be tested in an appropriate context. In addition, immunotherapy of lung cancer is guided by the status of programmed death-ligand 1 expression in tumor cells. The variety and versatility of cytological specimen preparations offer significant advantages for molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is important, not only from a lung cancer diagnosis, but also for the large number of ancillary studies that are necessary to provide appropriate clinical management. A large proportion of lung cancers is diagnosed by aspiration or exfoliative cytology specimens; thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. In this review, we discuss the opportunities and challenges of using cytologic specimens for biomarker testing of lung cancer and the role of cytopathology in the molecular era.

每个晚期非小细胞肺癌(NSCLC)患者都应该进行靶向驱动突变和基因排列检测,这可能为靶向治疗开辟道路。由于大多数处于疾病晚期的非小细胞肺癌患者不适合手术,这些检查必须在小活检或细胞学样本上进行。在不久的将来,越来越多的其他具有靶向突变的基因变化可能是可以治疗的。为了确定可能从新型靶向治疗中获益的患者,应在适当的背景下检测相关标记物。此外,肺癌的免疫治疗是由肿瘤细胞中程序性死亡配体1的表达状态来指导的。细胞学标本制备的多样性和多功能性为分子检测提供了显著的优势;然而,它们经常没有得到充分利用。因此,评估细胞学标本的效用和充分性是很重要的,不仅从肺癌诊断,而且对大量的辅助研究是必要的,以提供适当的临床管理。很大一部分肺癌是通过抽吸或剥脱细胞学标本诊断的;因此,优化分诊策略,最好地利用组织进行诊断和生物标志物研究,是肺癌管理的关键组成部分。在这篇综述中,我们讨论了利用细胞学标本进行肺癌生物标志物检测的机遇和挑战,以及细胞病理学在分子时代的作用。
{"title":"Biomarker testing of cytology specimens in personalized medicine for lung cancer patients.","authors":"Hyojin Kim,&nbsp;Jin-Haeng Chung","doi":"10.4132/jptm.2022.10.17","DOIUrl":"https://doi.org/10.4132/jptm.2022.10.17","url":null,"abstract":"<p><p>Every patient with advanced non-small cell lung cancer (NSCLC) should be tested for targetable driver mutations and gene arrangements that may open avenues for targeted therapy. As most patients with NSCLC in the advanced stage of the disease are not candidates for surgery, these tests have to be performed on small biopsies or cytology samples. A growing number of other genetic changes with targetable mutations may be treatable in the near future. To identify patients who might benefit from novel targeted therapy, relevant markers should be tested in an appropriate context. In addition, immunotherapy of lung cancer is guided by the status of programmed death-ligand 1 expression in tumor cells. The variety and versatility of cytological specimen preparations offer significant advantages for molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is important, not only from a lung cancer diagnosis, but also for the large number of ancillary studies that are necessary to provide appropriate clinical management. A large proportion of lung cancers is diagnosed by aspiration or exfoliative cytology specimens; thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. In this review, we discuss the opportunities and challenges of using cytologic specimens for biomarker testing of lung cancer and the role of cytopathology in the molecular era.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/0f/jptm-2022-10-17.PMC9682222.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40672109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The application of high-throughput proteomics in cytopathology. 高通量蛋白质组学在细胞病理学中的应用。
IF 2.4 Q2 Medicine Pub Date : 2022-11-01 Epub Date: 2022-11-09 DOI: 10.4132/jptm.2022.08.30
Ilias P Nikas, Han Suk Ryu

High-throughput genomics and transcriptomics are often applied in routine pathology practice to facilitate cancer diagnosis, assess prognosis, and predict response to therapy. However, the proteins rather than nucleic acids are the functional molecules defining the cellular phenotype in health and disease, whereas genomic profiling cannot evaluate processes such as the RNA splicing or posttranslational modifications and gene expression does not necessarily correlate with protein expression. Proteomic applications have recently advanced, overcoming the issue of low depth, inconsistency, and suboptimal accuracy, also enabling the use of minimal patient-derived specimens. This review aims to present the recent evidence regarding the use of high-throughput proteomics in both exfoliative and fine-needle aspiration cytology. Most studies used mass spectrometry, as this is associated with high depth, sensitivity, and specificity, and aimed to complement the traditional cytomorphologic diagnosis, in addition to identify novel cancer biomarkers. Examples of diagnostic dilemmas subjected to proteomic analysis included the evaluation of indeterminate thyroid nodules or prediction of lymph node metastasis from thyroid cancer, also the differentiation between benign and malignant serous effusions, pancreatic cancer from autoimmune pancreatitis, non-neoplastic from malignant biliary strictures, and benign from malignant salivary gland tumors. A few cancer biomarkers-related to diverse cancers involving the breast, thyroid, bladder, lung, serous cavities, salivary glands, and bone marrow-were also discovered. Notably, residual liquid-based cytology samples were suitable for satisfactory and reproducible proteomic analysis. Proteomics could become another routine pathology platform in the near future, potentially by using validated multi-omics protocols.

高通量基因组学和转录组学通常应用于常规病理实践,以促进癌症诊断、评估预后和预测治疗反应。然而,蛋白质而不是核酸是定义健康和疾病中细胞表型的功能分子,而基因组谱不能评估RNA剪接或翻译后修饰等过程,基因表达不一定与蛋白质表达相关。蛋白质组学的应用最近取得了进展,克服了低深度、不一致和次优精度的问题,也使使用最小的患者来源标本成为可能。这篇综述旨在介绍高通量蛋白质组学在剥脱和细针穿刺细胞学中使用的最新证据。大多数研究使用质谱法,因为它具有高深度、灵敏度和特异性,旨在补充传统的细胞形态学诊断,以及识别新的癌症生物标志物。应用蛋白质组学分析的诊断难题包括不确定甲状腺结节的评估或甲状腺癌淋巴结转移的预测,良恶性浆液积液的鉴别,自身免疫性胰腺炎与胰腺癌的鉴别,恶性胆道狭窄与非肿瘤性的鉴别,以及良性与恶性唾液腺肿瘤的鉴别。研究人员还发现了一些与乳腺癌、甲状腺癌、膀胱癌、肺癌、浆液腔、唾液腺和骨髓等多种癌症相关的癌症生物标志物。值得注意的是,残留的液基细胞学样本适用于令人满意和可重复的蛋白质组学分析。在不久的将来,蛋白质组学可能会成为另一种常规病理平台,可能会使用经过验证的多组学协议。
{"title":"The application of high-throughput proteomics in cytopathology.","authors":"Ilias P Nikas,&nbsp;Han Suk Ryu","doi":"10.4132/jptm.2022.08.30","DOIUrl":"https://doi.org/10.4132/jptm.2022.08.30","url":null,"abstract":"<p><p>High-throughput genomics and transcriptomics are often applied in routine pathology practice to facilitate cancer diagnosis, assess prognosis, and predict response to therapy. However, the proteins rather than nucleic acids are the functional molecules defining the cellular phenotype in health and disease, whereas genomic profiling cannot evaluate processes such as the RNA splicing or posttranslational modifications and gene expression does not necessarily correlate with protein expression. Proteomic applications have recently advanced, overcoming the issue of low depth, inconsistency, and suboptimal accuracy, also enabling the use of minimal patient-derived specimens. This review aims to present the recent evidence regarding the use of high-throughput proteomics in both exfoliative and fine-needle aspiration cytology. Most studies used mass spectrometry, as this is associated with high depth, sensitivity, and specificity, and aimed to complement the traditional cytomorphologic diagnosis, in addition to identify novel cancer biomarkers. Examples of diagnostic dilemmas subjected to proteomic analysis included the evaluation of indeterminate thyroid nodules or prediction of lymph node metastasis from thyroid cancer, also the differentiation between benign and malignant serous effusions, pancreatic cancer from autoimmune pancreatitis, non-neoplastic from malignant biliary strictures, and benign from malignant salivary gland tumors. A few cancer biomarkers-related to diverse cancers involving the breast, thyroid, bladder, lung, serous cavities, salivary glands, and bone marrow-were also discovered. Notably, residual liquid-based cytology samples were suitable for satisfactory and reproducible proteomic analysis. Proteomics could become another routine pathology platform in the near future, potentially by using validated multi-omics protocols.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cd/a6/jptm-2022-08-30.PMC9682220.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40672576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Development of quality assurance program for digital pathology by the Korean Society of Pathologists. 韩国病理学家协会数字病理学质量保证计划的发展。
IF 2.4 Q2 Medicine Pub Date : 2022-11-01 Epub Date: 2022-11-15 DOI: 10.4132/jptm.2022.09.30
Yosep Chong, Jeong Mo Bae, Dong Wook Kang, Gwangil Kim, Hye Seung Han

Background: Digital pathology (DP) using whole slide imaging is a recently emerging game changer technology that can fundamentally change the way of working in pathology. The Digital Pathology Study Group (DPSG) of the Korean Society of Pathologists (KSP) published a consensus report on the recommendations for pathologic practice using DP. Accordingly, the need for the development and implementation of a quality assurance program (QAP) for DP has been raised.

Methods: To provide a standard baseline reference for internal and external QAP for DP, the members of the Committee of Quality Assurance of the KSP developed a checklist for the Redbook and a QAP trial for DP based on the prior DPSG consensus report. Four leading institutes participated in the QAP trial in the first year, and we gathered feedback from these institutes afterwards.

Results: The newly developed checklists of QAP for DP contain 39 items (216 score): eight items for quality control of DP systems; three for DP personnel; nine for hardware and software requirements for DP systems; 15 for validation, operation, and management of DP systems; and four for data security and personal information protection. Most participants in the QAP trial replied that continuous education on unfamiliar terminology and more practical experience is demanding.

Conclusions: The QAP for DP is essential for the safe implementation of DP in pathologic practice. Each laboratory should prepare an institutional QAP according to this checklist, and consecutive revision of the checklist with feedback from the QAP trial for DP needs to follow.

背景:数字病理(DP)使用整个幻灯片成像是最近出现的游戏规则改变者技术,可以从根本上改变病理工作的方式。韩国病理学家协会(KSP)的数字病理研究组(DPSG)发表了一份关于使用DP的病理实践建议的共识报告。因此,开发和实施DP质量保证程序(QAP)的必要性已被提出。方法:为了给DP的内部和外部QAP提供一个标准的基线参考,KSP质量保证委员会的成员根据先前的DPSG共识报告制定了一份红皮书清单和DP的QAP试验。第一年有四家领先的机构参与了QAP试验,之后我们收集了这些机构的反馈。结果:新编制的质量保证程序(QAP)清单共包含39项(216分),其中8项为质量保证系统的质量控制;DP人员3人;九是DP系统的软硬件要求;负责DP系统的验证、运行和管理;四是数据安全和个人信息保护。QAP试验的大多数参与者回答说,对不熟悉的术语和更多实际经验的持续教育是需要的。结论:DP的QAP对DP在病理实践中的安全实施至关重要。每个实验室应根据该清单编制机构QAP,并根据DP QAP试验的反馈对清单进行连续修订。
{"title":"Development of quality assurance program for digital pathology by the Korean Society of Pathologists.","authors":"Yosep Chong,&nbsp;Jeong Mo Bae,&nbsp;Dong Wook Kang,&nbsp;Gwangil Kim,&nbsp;Hye Seung Han","doi":"10.4132/jptm.2022.09.30","DOIUrl":"https://doi.org/10.4132/jptm.2022.09.30","url":null,"abstract":"<p><strong>Background: </strong>Digital pathology (DP) using whole slide imaging is a recently emerging game changer technology that can fundamentally change the way of working in pathology. The Digital Pathology Study Group (DPSG) of the Korean Society of Pathologists (KSP) published a consensus report on the recommendations for pathologic practice using DP. Accordingly, the need for the development and implementation of a quality assurance program (QAP) for DP has been raised.</p><p><strong>Methods: </strong>To provide a standard baseline reference for internal and external QAP for DP, the members of the Committee of Quality Assurance of the KSP developed a checklist for the Redbook and a QAP trial for DP based on the prior DPSG consensus report. Four leading institutes participated in the QAP trial in the first year, and we gathered feedback from these institutes afterwards.</p><p><strong>Results: </strong>The newly developed checklists of QAP for DP contain 39 items (216 score): eight items for quality control of DP systems; three for DP personnel; nine for hardware and software requirements for DP systems; 15 for validation, operation, and management of DP systems; and four for data security and personal information protection. Most participants in the QAP trial replied that continuous education on unfamiliar terminology and more practical experience is demanding.</p><p><strong>Conclusions: </strong>The QAP for DP is essential for the safe implementation of DP in pathologic practice. Each laboratory should prepare an institutional QAP according to this checklist, and consecutive revision of the checklist with feedback from the QAP trial for DP needs to follow.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/d7/jptm-2022-09-30.PMC9682224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40700794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: its updated diagnostic criteria, preoperative cytologic diagnoses and impact on the risk of malignancy. 具有乳头状核特征的无创甲状腺滤泡性肿瘤:其最新诊断标准、术前细胞学诊断及其对恶性肿瘤风险的影响
IF 2.4 Q2 Medicine Pub Date : 2022-11-01 Epub Date: 2022-11-09 DOI: 10.4132/jptm.2022.09.29
Hee Young Na, So Yeon Park

Due to the extremely indolent behavior, a subset of noninvasive encapsulated follicular variant papillary thyroid carcinomas has been classified as "noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)" since 2016 and is no longer considered carcinoma. Since the introduction of this new terminology, changes and refinements have been made in diagnostic criteria. Initially, the incidence of NIFTP was estimated substantial. However, the reported incidence of NIFTP varies greatly among studies and regions, with higher incidence in North American and European countries than in Asian countries. Thus, the changes in the risk of malignancy (ROM) in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) differ inevitably among regions. Because more conservative surgery is recommended for NIFTPs, distinguishing NIFTPs from papillary thyroid carcinomas in preoperative fine-needle aspiration cytology became one of the major concerns. This review will provide comprehensive overview of updates on diagnostic criteria, actual incidence and preoperative cytologic diagnoses of NIFTP, and its impact on the ROM in TBSRTC.

由于其极其惰性的行为,自2016年起,一部分无创包膜滤泡变异型甲状腺乳头状癌被归类为“具有乳头样核特征的无创滤泡性甲状腺肿瘤(NIFTP)”,不再被认为是癌。自从引入这个新术语以来,在诊断标准中进行了更改和改进。最初,估计NIFTP的发生率很高。然而,不同研究和地区报告的NIFTP发病率差异很大,北美和欧洲国家的发病率高于亚洲国家。因此,在Bethesda甲状腺细胞病理学报告系统(TBSRTC)中,恶性肿瘤(ROM)风险的变化不可避免地在不同地区有所不同。由于NIFTPs推荐更多的保守手术,术前细针穿刺细胞学检查区分NIFTPs和甲状腺乳头状癌成为主要关注的问题之一。本文将全面综述NIFTP的诊断标准、实际发病率和术前细胞学诊断的最新进展,以及它对TBSRTC患者ROM的影响。
{"title":"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: its updated diagnostic criteria, preoperative cytologic diagnoses and impact on the risk of malignancy.","authors":"Hee Young Na,&nbsp;So Yeon Park","doi":"10.4132/jptm.2022.09.29","DOIUrl":"https://doi.org/10.4132/jptm.2022.09.29","url":null,"abstract":"<p><p>Due to the extremely indolent behavior, a subset of noninvasive encapsulated follicular variant papillary thyroid carcinomas has been classified as \"noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)\" since 2016 and is no longer considered carcinoma. Since the introduction of this new terminology, changes and refinements have been made in diagnostic criteria. Initially, the incidence of NIFTP was estimated substantial. However, the reported incidence of NIFTP varies greatly among studies and regions, with higher incidence in North American and European countries than in Asian countries. Thus, the changes in the risk of malignancy (ROM) in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) differ inevitably among regions. Because more conservative surgery is recommended for NIFTPs, distinguishing NIFTPs from papillary thyroid carcinomas in preoperative fine-needle aspiration cytology became one of the major concerns. This review will provide comprehensive overview of updates on diagnostic criteria, actual incidence and preoperative cytologic diagnoses of NIFTP, and its impact on the ROM in TBSRTC.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/a4/jptm-2022-09-29.PMC9682216.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40672574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
What's new in soft tissue and bone pathology 2022-updates from the WHO classification 5th edition. 《软组织和骨骼病理学2022》的新内容——更新自世卫组织分类第5版。
IF 2.4 Q2 Medicine Pub Date : 2022-11-01 Epub Date: 2022-11-15 DOI: 10.4132/jptm.2022.10.18
Erica Y Kao, Jose G Mantilla

The 2020 release of the WHO Classification of Soft Tissue and Bone Tumors, 5th edition, contains several changes driven by new knowledge in the field. These include reclassification of some entities, refinement of risk classification systems, and the inclusion of novel disease processes, many of which are driven by recurrent gene fusions. The most notable changes are described here.

2020年发布的《世卫组织软组织和骨肿瘤分类》第5版包含了由该领域新知识推动的若干变化。这些措施包括对某些实体进行重新分类,改进风险分类系统,并纳入新的疾病过程,其中许多是由复发性基因融合驱动的。这里描述了最显著的变化。
{"title":"What's new in soft tissue and bone pathology 2022-updates from the WHO classification 5th edition.","authors":"Erica Y Kao,&nbsp;Jose G Mantilla","doi":"10.4132/jptm.2022.10.18","DOIUrl":"https://doi.org/10.4132/jptm.2022.10.18","url":null,"abstract":"<p><p>The 2020 release of the WHO Classification of Soft Tissue and Bone Tumors, 5th edition, contains several changes driven by new knowledge in the field. These include reclassification of some entities, refinement of risk classification systems, and the inclusion of novel disease processes, many of which are driven by recurrent gene fusions. The most notable changes are described here.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/6f/jptm-2022-10-18.PMC9682218.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40700795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic distribution and pitfalls of glandular abnormalities in cervical cytology: a 25-year single-center study. 宫颈细胞学中腺体异常的诊断分布和缺陷:一项25年的单中心研究。
IF 2.4 Q2 Medicine Pub Date : 2022-11-01 Epub Date: 2022-11-09 DOI: 10.4132/jptm.2022.09.05
Jung-A Sung, Ilias P Nikas, Haeryoung Kim, Han Suk Ryu, Cheol Lee

Background: Detection of glandular abnormalities in Papanicolaou (Pap) tests is challenging. This study aimed to review our institute's experience interpreting such abnormalities, assess cytohistologic concordance, and identify cytomorphologic features associated with malignancy in follow-up histology.

Methods: Patients with cytologically-detected glandular lesions identified in our pathology records from 1995 to 2020 were included in this study.

Results: Of the 683,197 Pap tests performed, 985 (0.144%) exhibited glandular abnormalities, 657 of which had tissue follow-up available. One hundred eighty-eight cases were cytologically interpreted as adenocarcinoma and histologically diagnosed as malignant tumors of various origins. There were 213 cases reported as atypical glandular cells (AGC) and nine cases as adenocarcinoma in cytology, yet they were found to be benign in follow-up histology. In addition, 48 cases diagnosed with AGC and six with adenocarcinoma cytology were found to have cervical squamous lesions in follow-up histology, including four squamous cell carcinomas. Among the cytomorphological features examined, nuclear membrane irregularity, three-dimensional clusters, single-cell pattern, and presence of mitoses were associated with malignant histology in follow-up.

Conclusions: This study showed our institute's experience detecting glandular abnormalities in cervical cytology over a 25-year period, revealing the difficulty of this task. Nonetheless, the present study indicates that several cytological findings such as membrane irregularity, three-dimensional clusters, single-cell pattern, and evidence of proliferation could help distinguishing malignancy from a benign lesion.

背景:巴氏涂片(Pap)检查中腺体异常的检测具有挑战性。本研究旨在回顾我院解释此类异常的经验,评估细胞组织学一致性,并在随访组织学中确定与恶性肿瘤相关的细胞形态学特征。方法:本研究纳入了1995年至2020年在我们的病理记录中发现的细胞学检测的腺体病变患者。结果:在进行的683,197例巴氏试验中,985例(0.144%)显示腺体异常,其中657例有组织随访。188例细胞学诊断为腺癌,组织学诊断为各种来源的恶性肿瘤。其中细胞学表现为非典型腺细胞(AGC) 213例,腺癌9例,但随访组织学显示为良性。此外,48例诊断为AGC, 6例细胞学诊断为腺癌的患者在随访组织学中发现宫颈鳞状病变,其中4例为鳞状细胞癌。在检查的细胞形态学特征中,核膜不规则,三维簇状,单细胞模式和有丝分裂的存在与随访的恶性组织学有关。结论:本研究总结了我院25年来检测宫颈细胞学中腺体异常的经验,揭示了这项工作的难度。尽管如此,目前的研究表明,一些细胞学上的发现,如膜不规则、三维聚集、单细胞模式和增殖的证据,可以帮助区分恶性和良性病变。
{"title":"Diagnostic distribution and pitfalls of glandular abnormalities in cervical cytology: a 25-year single-center study.","authors":"Jung-A Sung,&nbsp;Ilias P Nikas,&nbsp;Haeryoung Kim,&nbsp;Han Suk Ryu,&nbsp;Cheol Lee","doi":"10.4132/jptm.2022.09.05","DOIUrl":"https://doi.org/10.4132/jptm.2022.09.05","url":null,"abstract":"<p><strong>Background: </strong>Detection of glandular abnormalities in Papanicolaou (Pap) tests is challenging. This study aimed to review our institute's experience interpreting such abnormalities, assess cytohistologic concordance, and identify cytomorphologic features associated with malignancy in follow-up histology.</p><p><strong>Methods: </strong>Patients with cytologically-detected glandular lesions identified in our pathology records from 1995 to 2020 were included in this study.</p><p><strong>Results: </strong>Of the 683,197 Pap tests performed, 985 (0.144%) exhibited glandular abnormalities, 657 of which had tissue follow-up available. One hundred eighty-eight cases were cytologically interpreted as adenocarcinoma and histologically diagnosed as malignant tumors of various origins. There were 213 cases reported as atypical glandular cells (AGC) and nine cases as adenocarcinoma in cytology, yet they were found to be benign in follow-up histology. In addition, 48 cases diagnosed with AGC and six with adenocarcinoma cytology were found to have cervical squamous lesions in follow-up histology, including four squamous cell carcinomas. Among the cytomorphological features examined, nuclear membrane irregularity, three-dimensional clusters, single-cell pattern, and presence of mitoses were associated with malignant histology in follow-up.</p><p><strong>Conclusions: </strong>This study showed our institute's experience detecting glandular abnormalities in cervical cytology over a 25-year period, revealing the difficulty of this task. Nonetheless, the present study indicates that several cytological findings such as membrane irregularity, three-dimensional clusters, single-cell pattern, and evidence of proliferation could help distinguishing malignancy from a benign lesion.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/27/jptm-2022-09-05.PMC9682225.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40672573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Journal of Pathology and Translational Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1